Last updated on September 2017

Phase II/III Randomized study of Sorafenib plus Doxorubicin versus sorafenib in patients with advanced HCC


Other Details:

For more information, please contact:
844.229.3710
646.776.7532 (local)
Bayer@emergingmed.com

For Study Locations, Click Here



Find a site near you

Start Over

Research Center

Located in: Additional Locations, WA USA
2.55miles
  Connect »

Research Center

Located In: Additional Locations, MD USA
2.55miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.